logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Chemical Intermediates > Piperaquinoline CAS 4085-31-8

Piperaquinoline CAS 4085-31-8

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 4085-31-8

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
4085-31-8
Appearance::
Off-white Powder
Molecular Formula::
C29H32Cl2N6
Molecular Weight::
535.51100
EINECS NO::
NA
MDL NO::
MFCD01237079
CAS NO::
4085-31-8
Appearance::
Off-white Powder
Molecular Formula::
C29H32Cl2N6
Molecular Weight::
535.51100
EINECS NO::
NA
MDL NO::
MFCD01237079
Piperaquinoline CAS 4085-31-8

Product Description:

Product Name: Piperaquinoline CAS NO: 4085-31-8

 

 

Synonyms:

7-Chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline;

Piperaquine tetraphosphate tetrahydrate;

 

 

Chemical & Physical Properties:

Appearance: Off-white powder

Assay :≥99.00%

Density: 1.292g/cm3

Boiling Point: 721.1℃ at 760 mmHg

Flash Point: 389.9℃

Refractive Index: 1.664

Vapour Pressure: 0.0±2.3 mmHg at 25℃

 

 

Safety Information:

HS Code: 2942000000

 

 

Piperaquine is an antimalarial drug, a bisquinoline first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. Usage declined in the 1980s as piperaquine-resistant strains of P. falciparum arose and artemisinin-based antimalarials became available. However, Chinese scientists have been studying whether piperaquine can still be used therapeutically in combination with artemisinin.

Piperaquine is characterized by slow absorption and a long biological half-life, making it a good partner drug with artemisinin derivatives which are fast acting but have a short biological half-life.

The fixed-dose combination dihydroartemisinin-piperaquine (Eurartesim) was submitted for approval to the European Medicines Agency in 2009.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.